Incannex company presentation – results from phase 1 clinical trial to assess proprietary ihl-675a

Melbourne, australia, may 03, 2023 (globe newswire) -- incannex healthcare ltd (nasdaq: ixhl) (asx: ihl) (‘incannex' or ‘the company') is pleased to announce a company presentation containing data and analysis of the results from the phase 1 clinical trial undertaken to assess safety and pharmacokinetics of ihl-675a as an anti-inflammatory drug candidate.
IXHL Ratings Summary
IXHL Quant Ranking